Evidence map›Paper›PMID 29722920›Full record

ArticleCancer medicine2018

Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: a long-term Danish cohort study.

Ulrick Espelund, Andrew G Renehan, Søren Cold, Claus Oxvig, Lee Lancashire, Zhenqiang Su, Allan Flyvbjerg, Jan Frystyk

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Ulrick EspelundMedical Research Laboratory, Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.
Andrew G RenehanThe Christie NHS Foundation Trust, Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Søren ColdDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Claus OxvigDepartment of Molecular Biology and Genetics, Science and Technology, Aarhus University, Aarhus, Denmark.
Lee LancashireClarivate Analytics, London, UK.
Zhenqiang SuClarivate Analytics, London, UK.
Allan FlyvbjergMedical Research Laboratory, Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.
Jan FrystykMedical Research Laboratory, Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-5379-0961
Aarhus University · DKClarivate (United States) · USManchester Academic Health Science Centre · GBOdense University Hospital · DKUniversity of Copenhagen · DKUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurement of circulating insulin-like growth factors (IGFs), in particular IGF-binding protein (IGFBP)-2, at the time of diagnosis, is independently prognostic in many cancers, but its clinical performance against other routinely determined prognosticators has not been examined. We measured IGF-I, IGF-II, pro-IGF-II, IGF bioactivity, IGFBP-2, -3, and pregnancy-associated plasma protein A (PAPP-A), an IGFBP regulator, in baseline samples of 301 women with breast cancer treated on four protocols (Odense, Denmark: 1993-1998). We evaluated performance characteristics (expressed as area under the curve, AUC) using Cox regression models to derive hazard ratios (HR) with 95% confidence intervals (CIs) for 10-year recurrence-free survival (RFS) and overall survival (OS), and compared those against the clinically used Nottingham Prognostic Index (NPI). We measured the same biomarkers in 531 noncancer individuals to assess multidimensional relationships (MDR), and evaluated additional prognostic models using survival artificial neural network (SANN) and survival support vector machines (SSVM), as these enhance capture of MDRs. For RFS, increasing concentrations of circulating IGFBP-2 and PAPP-A were independently prognostic [HR

Indexed as

Breast NeoplasmsCohort StudiesFemaleHumansInsulin-Like Growth Factor Binding Protein 2Middle AgedPregnancy-Associated Plasma Protein-APrognosisProgression-Free SurvivalSurvival RateInsulin-Like Growth Factor Binding Protein 2Pregnancy-Associated Plasma Protein-ABreast neoplasmsinsulin-like growth factor-binding protein 2pregnancy-associated plasma protein A

Identifiers

PMID29722920
PMCPMC6010701
OpenAlexW2800191736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.